TrialCancer science2020

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.

Naohiro Sekiguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.